Lab1636 — Harvard–Deerfield R&D Alliance
Supports collaboration between Harvard and Deerfield to advance novel therapeutic discoveries toward clinical validation for patient impact.
Lab1636 is a major strategic translational research alliance between Harvard University and Deerfield Management, a healthcare-focused investment firm, established to catalyze the development of novel therapeutics and rapidly drive Harvard biomedical innovations toward clinical validation. Deerfield Management committed $100 million to establish the alliance, making Lab1636 one of the largest indu…
Drug discovery and development of novel therapeutics for biomedical conditions, targeting clinical validation through the $100M Harvard–Deerfield translational research alliance.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see the timeline
Guides for this application
All guides →Grants for Biotech Startups: NIH, NSF, SBIR/STTR, and Non-Dilutive Funding
A practical guide to grants for biotech startups, including NIH SBIR/STTR, NSF, translational funding, evidence, regulatory readiness, and budgets.
DocumentsGrant Work Plan Template: Work Packages, Gantt, Milestones, and Risks
Use this grant work plan template to structure work packages, tasks, owners, deliverables, Gantt timing, dependencies, and risk registers.
Write proposalGrant Letter of Intent: How to Write an LOI or Letter of Inquiry
Learn what a grant letter of intent is, when funders ask for LOIs or letters of inquiry, what to include, what to avoid, and how funder rules differ.
More from Harvard OTD
All grants from this funder →Blavatnik Biomedical Accelerator
🇺🇸Harvard OTD · United States
Offers Harvard biomedical innovators pilot support for early proof-of-concept delivery.
Harvard Grid Accelerator — Awards
🇺🇸Harvard OTD · United States
Offers Harvard engineering teams startup support to take inventions from laboratory development to commercialization outcomes.
Similar grants
Browse the directory →
NIMHD SBIR Phase IIB Strategic Breakthrough Award
🇺🇸NIMHD · United States
Funds prior NIH SBIR and STTR Phase II small businesses bridging later-stage R&D to commercialization.
NCATS Preclinical Proof of Concept Studies for Rare Diseases
🇺🇸NCATS · United States
Funds U.S. researchers and companies conducting preclinical efficacy studies to advance therapeutic candidates for rare diseases toward IND applications.
NIAMS SBIR — Small Business Innovation Research
🇺🇸NIAMS · United States
Supports small businesses and researchers advancing arthritis, skin, and musculoskeletal innovation through staged aid.
NCATS Clinical Trial Readiness for Rare Diseases
🇺🇸NCATS · United States
Funds U.S. researchers and companies generating natural history data, biomarkers, and outcome measures needed to design clinical trials for rare diseases.
NHLBI Catalyze — Reissue
🇺🇸NHLBI · United States
Supports NHLBI translational pathways toward first-in-human feasibility testing.
NICHD R01 Research Project Grant
🇺🇸NICHD · United States
Supports investigator-led biomedical studies across the NICHD portfolio in the United States.